[HTML][HTML] First-line cisplatin, docetaxel, and cetuximab for patients with recurrent or metastatic head and neck cancer: A multicenter cohort study
A Falco, M Leiva, A Blanco, G Cefarelli… - World Journal of …, 2022 - ncbi.nlm.nih.gov
BACKGROUND The targeted therapy cetuximab [directed at the epidermal growth factor
receptor (EGFR)] in combination with 5-fluorouracil and platinum-based chemotherapy (the …
receptor (EGFR)] in combination with 5-fluorouracil and platinum-based chemotherapy (the …
[HTML][HTML] An effective and well-tolerated strategy in recurrent and/or metastatic head and neck cancer: successive lines of active chemotherapeutic agents
J Péron, V Polivka, S Chabaud, M Poupart, P Ceruse… - BMC cancer, 2014 - Springer
Background The combination platinum, 5-fluorouracil (5-FU) and cetuximab is the standard
first-line regimen of recurrent and/or metastatic head and neck squamous cell carcinoma …
first-line regimen of recurrent and/or metastatic head and neck squamous cell carcinoma …
[HTML][HTML] Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter …
J Guigay, J Fayette, AF Dillies, C Sire, JN Kerger… - Annals of …, 2015 - Elsevier
Background Cetuximab in combination with platinum and 5-fluorouracil is the standard of
care in the first-line treatment of patients with recurrent/metastatic head and neck squamous …
care in the first-line treatment of patients with recurrent/metastatic head and neck squamous …
Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck …
J Guigay, A Aupérin, J Fayette, E Saada-Bouzid… - The Lancet …, 2021 - thelancet.com
Background Results from a phase 2 trial of the TPEx chemotherapy regimen (docetaxel–
platinum–cetuximab) showed promising results, with a median overall survival of 14· 0 …
platinum–cetuximab) showed promising results, with a median overall survival of 14· 0 …
First line cetuximab and cisplatin with or without paclitaxel in recurrent/metastatic head and neck cancer: a randomized phase IIb trial
P Bossi, LH Hollander, R Miceli, D Ferrari… - Annals of …, 2017 - annalsofoncology.org
Background: Cisplatin (Cis), continuous infusion 5FU and Cetuximab (Cet)(EXTREME) first-
line treatment extends overall survival (OS) over Cis and 5FU of recurrent/metastatic …
line treatment extends overall survival (OS) over Cis and 5FU of recurrent/metastatic …
[HTML][HTML] TTCC-2019-02: real-world evidence of first-line cetuximab plus paclitaxel in recurrent or metastatic squamous cell carcinoma of the head and neck
J Rubió-Casadevall, B Cirauqui Cirauqui… - Frontiers in …, 2023 - frontiersin.org
Objectives The aim of this study was to confirm the efficacy of the ERBITAX scheme
(paclitaxel 80 mg/m2 weekly and cetuximab 400 mg/m2 loading dose, and then 250 mg/m2 …
(paclitaxel 80 mg/m2 weekly and cetuximab 400 mg/m2 loading dose, and then 250 mg/m2 …
[HTML][HTML] Cetuximab (C), Fluorouracil (F) and Cisplatin (P) Alone or with Docetaxel (D) for Recurrent/Metastatic (Rm) Head and Neck Cancer (Hnscc). Final Analysis of …
M Knoedler, T Gauler, A Dietz, V Grünwald… - Annals of …, 2014 - Elsevier
Aim: Analysis of a trial investigating, whether TPFC would be feasible and superior to PFC in
patients with RM-HNSCC without limiting comorbidities, based on the findings, that D in …
patients with RM-HNSCC without limiting comorbidities, based on the findings, that D in …
[HTML][HTML] Modified biweekly cisplatin, docetaxel plus cetuximab (TPEx) as first-line treatment for patients with recurrent/metastatic head and neck cancer
H Fuchs, J Pammer, C Minichsdorfer, D Posch… - Medical Oncology, 2018 - Springer
Three weekly high-dose chemotherapy regimens in combination with weekly cetuximab are
the treatment of choice for patients with recurrent/metastatic (R/M) head and neck squamous …
the treatment of choice for patients with recurrent/metastatic (R/M) head and neck squamous …
[HTML][HTML] Docetaxel plus cetuximab biweekly is an active regimen for the first-line treatment of patients with recurrent/metastatic head and neck cancer
D Posch, H Fuchs, G Kornek, A Grah, J Pammer… - Scientific Reports, 2016 - nature.com
For patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma
(SCCHN) limited therapeutic options exist. Only a subset of patients is suitable for …
(SCCHN) limited therapeutic options exist. Only a subset of patients is suitable for …
First‐line cetuximab+ platinum‐based therapy for recurrent/metastatic head and neck squamous cell carcinoma: A real‐world observational study—ENCORE
C Le Tourneau, M Ghiani, MC Cau, R Depenni… - Cancer …, 2023 - Wiley Online Library
Background ENCORE, an observational, prospective, open‐label study, investigated real‐
world treatment practices and outcomes with cetuximab plus platinum‐based therapy (PBT) …
world treatment practices and outcomes with cetuximab plus platinum‐based therapy (PBT) …